Axel Gschwind
Overview
Explore the profile of Axel Gschwind including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gschwind A, Ossowski S
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075562
Background: Immune checkpoint inhibitors (ICIs) have demonstrated significantly improved clinical efficacy in a minority of patients with advanced melanoma, whereas non-responders potentially suffer from severe side effects and delays in...
2.
Menzel M, Ossowski S, Kral S, Metzger P, Horak P, Marienfeld R, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):106.
PMID: 37864096
A growing number of druggable targets and national initiatives for precision oncology necessitate broad genomic profiling for many cancer patients. Whole exome sequencing (WES) offers unbiased analysis of the entire...
3.
Abdel-Salam G, Hellmuth S, Gradhand E, Kaseberg S, Winter J, Pabst A, et al.
JCI Insight
. 2023 Oct;
8(22).
PMID: 37796616
MAD2L1BP-encoded p31comet mediates Trip13-dependent disassembly of Mad2- and Rev7-containing complexes and, through this antagonism, promotes timely spindle assembly checkpoint (SAC) silencing, faithful chromosome segregation, insulin signaling, and homology-directed repair (HDR)...
4.
Liebmann A, Admard J, Armeanu-Ebinger S, Wild H, Abele M, Gschwind A, et al.
EBioMedicine
. 2023 Sep;
96:104797.
PMID: 37716236
Background: Genomic characterisation has led to an improved understanding of adult melanoma. However, the aetiology of melanoma in children is still unclear and identifying the correct diagnosis and therapeutic strategies...
5.
Mittelstadt S, Kelemen O, Admard J, Gschwind A, Koch A, Worz S, et al.
Br J Cancer
. 2023 Mar;
128(11):2097-2103.
PMID: 36973448
Background: HPV-related cervical cancer (CC) is the fourth most frequent cancer in women worldwide. Cell-free tumour DNA is a potent biomarker to detect treatment response, residual disease, and relapse. We...
6.
Renovanz M, Kurz S, Rieger J, Walter B, Becker H, Hille H, et al.
Neurooncol Adv
. 2023 Mar;
5(1):vdad012.
PMID: 36915613
Background: The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular...
7.
Roggia C, Armeanu-Ebinger S, Gschwind A, Seibel-Kelemen O, Hertler S, Faust U, et al.
Eur J Cancer
. 2022 Dec;
179:48-55.
PMID: 36495689
Background: Sequencing of tumour tissue with comprehensive gene panels is increasingly used to guide treatment in precision oncology. Analysis of tumour-normal pairs allows in contrast to tumour-only assessment direct discrimination...
8.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, et al.
J Cancer Res Clin Oncol
. 2022 Feb;
149(2):833-840.
PMID: 35192052
Background: High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As...
9.
Hilke F, Sinnberg T, Gschwind A, Niessner H, Demidov G, Amaral T, et al.
Cancers (Basel)
. 2020 Aug;
12(9).
PMID: 32825510
The detection of somatic driver mutations by next-generation sequencing (NGS) is becoming increasingly important in the care of advanced melanoma patients. In our study, we evaluated the NGS results of...
10.
Forschner A, Hilke F, Bonzheim I, Gschwind A, Demidov G, Amaral T, et al.
Cancers (Basel)
. 2020 Mar;
12(3).
PMID: 32110946
Background: Mucosal and acral melanoma respond worse to immune checkpoint inhibitors (ICI) than cutaneous melanoma. as well as amplifications are supposed to be associated with hyperprogression on ICI in diverse...